Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia.
- Author:
Shao-Fei WANG
1
;
Ya-Jing HUANG
2
;
Chang-Lin YU
2
;
Qi-Yun SUN
2
;
Jian-Hui QIAO
2
;
Kai-Xun HU
2
;
Hong-Li ZUO
2
;
Zheng DONG
2
;
Zhi-Qing LIU
2
;
Yi WANG
2
;
Xiao-Mei HUANG
2
;
Hui-Sheng AI
2
;
Mei GUO
1
Author Information
- Publication Type:Journal Article
- MeSH: Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mycophenolic Acid; analogs & derivatives; Neutrophils; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine; analogs & derivatives
- From: Journal of Experimental Hematology 2015;23(4):1097-1102
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic efficacy of nonmyeloablative allogeneic hematopoietic stem cells transplantation for severe acquired aplastic anemia (SAA).
METHODSFourteen patients with severe acquired aplastic anemia received nonmyeloablative allogeneic hematopoietic stem cells transplantation from HLA matched sibling donors, among them 8 cases were dagnosed as SAA-I, 6 cases were diagnosed as SAA-II. The conditioning regimen consisted of fludarabine (FIUD), cyclophosphamide (CTX) and anti-thymocyte globulin (ATG/ALG). The prophylaxis for graft-versus-host disease (GVHD) was performed with cyclosporine (CsA) combined with mycophenolate mofetil (MMF) or tacrolimus (FK506).
RESULTSAll the patients gained a quick successfully engraftment of donor hametopoietic cells. The mean recovery time for neutrophil and platelet was 9 d and 13 d respectively. All the patients have acquired a full donor chimerism before 14 d. There were only 2 cases of GVHD: one out of them was acute skin GVHD (grade I) at day 70 after transplantation and the other was chronic liver GVHD (grade I) in 1 years after transplantation, the GVHD more than degree II did not coccur in all patients, 9 patients with bacterial and fungal mixed infection and (or) virus infection were observed, and improved after anti-infection therapy. The median follow-up time were 54.5 months (ranged between 5-144 months), and 12 patients remain disease-free survival currently, only 2 patients died of fungal infectin.
CONCLUSIONTransplantation of nonmyeloablative allogeneic hematopoietic stem cell is safe and effective for the treatment of severe acquired aplastic, but the prevention, treatment and monitoring of infection need to be enhance.